A new study suggests that Remdesivir may not help patients who have moderate cases of COVID-19.
A total of 584 patients with moderate COVID-19 received either a 5 or 10-day course of Remdesivir or standard care.
Those on the 10-day course of Remdesivir did not have a significant improvement in outcomes compared to those who did not receive the drug.
The death rate was also similar.
However, those on the 5-day course did improve compared to those who received standard care.
But the researchers say the difference was "of uncertain clinical importance."
